Search

1 to 10 of 494
Sort by

Web Page
February

February 2019 JITC Reading List February 2019 The following articles have been recommended for further reading in the field of cancer immunotherapy by JITC’s Editor-in-Chief, Dr. Pedro J. Romero. “Synthetic DNA-Encoded Monoclonal Antibody Delivery of Anti–CTLA-4 Antibodies Induces Tumor...


Web Page
JITC's Reading List

The Journal for ImmunoTherapy of Cancer (JITC), the official journal of the Society for Immunotherapy of Cancer (SITC), is a leading publication of original research articles, literature reviews, position papers and discussion on all aspects of tumor immunology and cancer immunotherapy–from...






Library Entry
Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a review of the concept of using OV as a unique type of cancer vaccine and the likely superior benefits that would be associated with integrating OVs into combination immunotherapies for improving objective clinical response...


Library Entry
A rare population of tumor antigen-specific CD4+CD8+ double-positive αβ T lymphocytes uniquely provide CD8-independent TCR genes for engineering therapeutic T cells

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a research article that describes the discovery of a naturally occurring T-cell clone which expressed high-affinity HLA-A*02:01 (A*02)-restricted TCR against NY-ESO-1 from a patient who had NY-ESO-1-expressing ovarian tumor. ...


Library Entry
EnanDIM - a novel family of L-nucleotide-protected TLR9 agonists for cancer immunotherapy

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a research article that evaluated the capacity of EnanDIM® molecules to modulate the tumor microenvironment (TME) and characterized the resulting anti-tumor effects, including long-term immune memory in various mouse tumor models. ...


Library Entry
Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-se

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a case report on patients treated with immune-checkpoint blockade followed by targeted therapy, or vice versa, who experienced cutaneous toxicities with unique histological patterns, a feature that has not been well described in...